Calendario›REGN›ALN-PNP

ALN-PNP

A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD

Ensayo de REGENERON PHARMACEUTICALS, INC. en Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (del registro, en inglés).

Fase

Fase 2

Estado

Reclutando pacientes

Participantes

204

previstos

Centros

9

Fin del objetivo primario

mar 2030

estimado por el promotor

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en may 2026.

Qué mide

Percent change in liver fat (From baseline at week 24) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis study will test a study drug called ALN-PNP with and without another drug that is used for controlling blood sugar, appetite, and weight (for example, tirzepatide), to see if it can help treat MASLD, also known as fatty liver disease. ALN-PNP reduces the amount of Patatin-like phospholipase domain-containing protein 3 (PNPLA3), a protein that liver cells make, which may help decrease liver fat if there is an abnormal PNPLA3 protein. The goal of this study is to understand the effect of ALN-PNP with or without tirzepatide on reducing liver fat. The study is looking at: * How well ALN-PNP with and without tirzepatide works * What side effects ALN-PNP might cause * How much ALN-PNP is in the blood at different times * How the body and the liver change after having ALN-PNP, which can help researchers understand why ALN-PNP works better in some people than others

Más ensayos de REGN

Todos los de REGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT07527910), actualizada en sep 2026.